Tiotropium / Respimat One-Year Study

Boehringer Ingelheim

Status and phase: Completed; Phase 3

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Tiotropium Inhalation Solution; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00168844

205.254

Details and patient eligibility

About

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

Enrollment: 983 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

983 participants in 3 patient groups

Tiotropium Respimat 5mcg (Tio R5)

Other group

Treatment:

Drug: Tiotropium Inhalation Solution

Tiotropium Respimat 10mcg (Tio R10)

Other group

Treatment:

Drug: Tiotropium Inhalation Solution

Placebo

Other group

Treatment:

Other: Placebo